Saftey and Efficacy of Cannabidiol (CBD), a Major Non-Psycotrobic Compound of Cannabis sativa Clinically Tested

Safety and Efficacy of Cannabidiol (CBD), a Major Non-Psycotrobic Compound of Cannabis sativa Clinically Tested

The active components in Cannabis have been studied in hundreds of studies. Recently at the University of Sao Paulo, investigators review over 130 of these papers assessing the impact of these compounds called cannabidiols, or CBDs. CBDs have been shown to have an impact in humans and animals in clinical trials. Studies have shown the effects of multiple cannibinoid extracts were excluded from analysis.

Several studies have suggested that CBDs are well tolerated in humans at high doses. It is also suggested that these compounds are non-toxic in normal cells. Studies also suggest that CBD does not have any impact on physiological functions like heart rate, blood pressure or body temperature, the gastrointestinal tract, or alter psychomotor functions.

A recent study showed safety and side effects of the Cannabis sativa constituent CBD.

Conclusions of the authors reporting the findings say that, “Based on recent advances in cannabinoid administration in humans, controlled CBD may be safe in humans and animals. However, further studies are needed to clarify these reported in vitro and in vivo side effects.”

The therapeutic properties of CBDs are well documented and studies of cannabinoids continue to see what ability they possess for a variety of therapeutic uses like: inflammation, diabetes, epilepsy, cancer, bone density and other health problems. However, CBD is still classified under federal law as a Schedule I drug, prohibited for possession and known to have “no medicinal use for treatment in the United States.”